

ANTI EPILEPTIC MEDICATIONS

Dr. Sangeeta Kamthan

Associate Professor

Department of Chemistry ,

Bareilly College , Bareilly (UP)

drdk62@yahoo.com

ABSTRACT

Since the early 1990s, a large number of novel antiepileptic medicines (AEDs) have hit the market. These AEDs provide notable benefits due to their favorable pharmacokinetics, increased tolerability, and reduced risk of drug-drug interactions. But in spite of the Thirty percent of epilepsy patients are still receiving treatment with traditional and novel AEDs Experience seizures. Consequently, there is still a huge need to create more effective AEDs for those with refractory epilepsy. Here, we review the developing understanding the pathological causes of epilepsy and how to apply it to develop of fresh treatments. We also detail the current strategy for AED discovery and Newer models of pharmacoresistance and epileptogenesis have certain distinctive characteristics that have developed recently. [1]

INTRODUCTION

Since the effects of drugs cannot be distinguished from those of seizures, first-generation drugs have received the most attention, the patient's genetic background, the mechanism of action and pharmacokinetic profile of AEDs, and the concurrent use of immunosuppressant drugs may all be confounding factors, data on the effects of antiepileptic drugs on the immune system are frequently inconsistent and occasionally contradictory. By influencing humoral and cellular immunity, it has been discovered that valproate, carbamazepine, phenytoin, vigabatrin, levetiracetam, and diazepam influence the immune system's function. There are pharmacokinetic interactions with AEDs (most frequently occurring with carbamazepine, phenytoin, phenobarbital and valproate). AEDs and immunotherapies (ACTH, dexamethasone, hydrocortisone, methylprednisolone, cyclophosphamide, methotrexate, rituximab) that include stimulation or inhibition of drug metabolism mostly interact with the liver. [3]

The therapeutic significance of these medication interactions isn't yet clear, though. Antiepileptic hypersensitivity syndrome (AHS), a potentially fatal, idiosyncratic cutaneous response to aromatic AEDs that causes end organ damage, is a significant adverse impact of AEDs on the immune system. It has been linked to phenytoin, carbamazepine, phenobarbital, lamotrigine, oxcarbazepine, felbamate, and zonisamide. Uncertainties exist about the pathogenic processes underlying AHS. [2] There are many different treatment approaches for treating epilepsy thanks to the recent introduction of several novel antiepileptic medications (AEDs). When choosing medications for specific epilepsy patients, knowledge of the AEDs' mechanisms of action is helpful. AEDs can be divided into those having various or varying modes of action, those acting at the excitatory synapse, those acting at the inhibitory synapse, those acting on the extrasynaptic neuronal membrane. Here, we succinctly review and demonstrate how AEDs affect neurons as well as other results that are relevant to the clinical side of epileptology. [3] There are many different treatment approaches for treating epilepsy thanks to the recent introduction of several novel antiepileptic medications (AEDs). [4] In this context, details about the sometimes understanding how AEDs work is helpful choosing medications for certain epilepsy sufferers. However, epileptologists could find it challenging to fully understand the range of AEDs' effects because multiple modes of action are included in many AEDs. [5] The outcomes of animal testing are not always applicable. to people patients. Furthermore, nomenclature used in neuronal physiology differs somewhat from that used in clinical epileptology. A "spike" is one epileptological example from the earlier area. Although not an epileptic, refers to an action potential discharge. Here, we aim to succinctly review the activity of AEDs and associated research.

Effects of Antiepileptic Drugs on Immunology

Recent research has highlighted the involvement of inflammation in the onset and durability of epileptic episodes. [6] The expression and synthesis of several molecules, namely cytokines, can be altered by AEDs, which can therefore have a direct impact on both humoral and cellular immunity. This regulatory impact may be caused by the direct way that AEDs affect the activity of specific transcription factors, most notably nuclear factor-kappaB (NF-B), by modifying that activity. [7] However, the supporting evidence is scant and contradictory, and it's frequently unclear how the effects work. It is sometimes challenging to distinguish the effects of AEDs from those of seizures or other potential confounding variables (e.g., intercurrent illness). According to some evidence, AEDs may be able to alter immune system function, which may either raise or lower the epileptic threshold notably.

The Discussion of some of the drugs are as follows such as Valporate , Carbamazepine, Vigabatrin, Diazepam, Phenytoin.

1. Valporate

In addition to treating epilepsy, bipolar disorder, and preventing migraines, the drug valproate (VPA) is also available in the forms of valproic acid, sodium valproate, and valproate semisodium. [8] In those who have absence seizures, partial seizures, or generalised seizures, they are helpful in preventing seizures. They can be administered intravenously or orally, and there are long- and short-acting versions of the tablet forms. [9] Valproate frequently causes dry mouth, nausea, vomiting, and somnolence as side effects. Liver failure is one example of a serious adverse effect. [10] The effects of valproate on the immune system are not well-documented found that monocytes and glia produced less cytokines, such as tumour necrosis factor (TNF)- and interleukin (IL)-6; this effect is likely brought on by valproate's inhibitory impact on NF-kB translocation to the nucleus.[11]

2. Carbamazepine

The anticonvulsant drug carbamazepine (CBZ), which is marketed under the brand name Tegretol among others, is primarily used to treat neuropathic pain and epilepsy. [12] It is utilised as a second-line drug for bipolar illness and as an adjuvant therapy for schizophrenia when other medicines are being taken. [13] For both focal and generalised seizures, carbamazepine seems to be equally effective as phenytoin and valproate. [14] Absence or myoclonic seizures cannot be treated with it. [15] After receiving AED treatment for a year, juvenile patients' blood levels of IL-1, IL-1, IL-2, and IL-6 increased according to their study on carbamazepine. The authors disregarded the impact of seizures on cytokines by comparing cytokine levels before and after carbamazepine. The results of the modulation of immunoglobulin (Ig) serum levels in response to carbamazepine are more ambiguous, with both elevated and reduced IgA, IgM, and IgG levels being recorded.

3. Vigabatrin

The drug Vigabatrin, often known by the brand name Sabril, is used to treat epilepsy. In 2019, it was made accessible as a generic drug. [16] It functions by preventing -aminobutyric acid from being broken down (GABA). Although it is a structural analogue of GABA and is also known as -vinyl-GABA, it does not attach to GABA receptors. [17] Vigabatrin is licenced for use as a monotherapy for infantile spasms in West syndrome, as an adjuvant treatment (in combination with other medications) for complex partial seizures, subsequent generalised seizures, and treatment-resistant epilepsy. [18] There is some evidence in the literature that vigabatrin can obstruct the cellular immune response. The percentage and absolute numbers of T and B lymphocytes, T-helper-inducer lymphocytes, and T-rosetting lymphocytes were not significantly different in controls and in children with epilepsy before and after treatment. However, the percentage and absolute numbers of T cytotoxic-suppressor lymphocytes and NK cells were significantly higher after 1 and 3 months of vigabatrin treatment, according to who studied 29 paediatric patients.

4. Diazepam

Diazepam, which was initially sold under the brand name Valium, is a benzodiazepine medication that has anxiolytic properties. A variety of disorders, including as anxiety, seizures, alcohol withdrawal syndrome, muscular spasms, sleeplessness, and restless legs syndrome are frequently treated with it. [19] Additionally, it could be administered during several medical operations to impair memory. It can be ingested orally, injected into the rectum, injected into a vein, injected into a muscle, or sprayed into the nose. Effects from injections into a vein might start in one to five minutes and extend for up to an hour. Affects within 15 to 60 minutes when taken orally. [20] Moodiness and coordination issues are frequent adverse effects. Serious adverse effects are uncommon. They consist of a higher suicide risk, reduced breathing. Only with this particular benzodiazepine have the effects on the immune system been researched. [20] Diazepam reduces interferon (IFN)- production via inhibiting human T-cell activity through peripheral benzodiazepine receptors. IFN- has antiviral and immunomodulatory properties, as is obvious. The natural resistance of IFN-knockout mice to bacterial, parasite, and viral infections was impaired. Infants with inadequate IFN- production had persistent infection as well as diminished NK cell and neutrophil activity. [21]

5. Phenytoin

One such anti-seizure drug is phenytoin (PHT), which is marketed under the trade names Dilantin and others. It helps to prevent focal and tonic-clonic seizures, popularly known as grand mal seizures, but not absence seizures. [22] For status epilepticus that does not respond to benzodiazepines, fosphenytoin is administered intravenously. Additionally, it may be used to treat certain cardiac arrhythmias or neuropathic discomfort. [23] It can be administered intravenously or orally. The intravenous form usually starts to function within 30 minutes and lasts for around 24 hours. To identify the right dosage, blood levels can be tested. Nausea, stomach discomfort, lack of appetite, sluggishness, faster hair growth, and gum swelling are typical adverse effects. [24] In individuals with epilepsy, this medication can result in a reduction in suppressor T cells and a reversible IgA deficit. The increased production of IL-6 and IL-8, along with elevated levels of basic fibroblast growth factor, which were seen in vitro using human gingival fibroblasts, are likely the causes of gingival overgrowth. This increase facilitates the recruitment and activation of inflammatory cells, which in turn sets the stage for the development of an interaction between cytokines and periodontal connective tissue cells. [25]

Antiepileptic drug and immunotherapy interactions

The immunological effects of epilepsy go beyond the immune system's depressed response to some anti-epileptic medications. Additionally, they include elements important for the pathogenesis of various types of as well as a number of clinical symptoms, epilepsy encountered in a small number of epileptic patients, although they are not always caused by the paroxysmal brain illness itself. [26] They also include therapeutic facets of anticonvulsive therapy and its alleged harmful effects. Convulsions and the impact of immunomodulating

therapy on the immune system. Not least of all, they include genetic relationships between several types of epilepsy and abnormalities in the immune system. [27] About 30% of epilepsy patients receive combination AED therapy (the use of two or more medications), and a sizeable portion of these patients may need to receive immunotherapies such as adrenocorticotrophic hormone (ACTH), corticosteroids (dexamethasone, hydrocortisone, prednisone/prednisolone, and methylprednisolone), cyclophosphamide, methotrexate, and r. However, these immunotherapies are not approved to treat epilepsy. [28] More pharmacokinetic interactions are linked to AEDs than any other therapeutic medication class. Carbamazepine, phenytoin, phenobarbital, and valproate interact extremely well. [29] Many of the more recent AEDs (such as gabapentin, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin, topiramate, tiagabine, vigabatrin, and zonisamide) have a lower tendency to interact and less potential to induce or inhibit enzymes. The AEDs that are renally removed (gabapentin, levetiracetam, pregabalin, and vigabatrin) have the lowest potential for interactions. [30] Epileptic seizures occur in around 10% of people with systemic lupus erythematosus (SLE) patients. The seizures are primarily primary generalized when they start before generalized SLE develops. [31] Therefore, long-term anti-epileptic medication therapy may trigger SLE, or epilepsy and SLE may both present as a result of a hereditary susceptibility. While using phenytoin, some people get IgA deficiency treatment. When phenytoin is stopped using, this condition can be reversed and IgA returns to normal (drug-induced IgA deficiency). Certain epileptic Patients have an IgA deficit unrelated to medications. [32] Typically, HLA-A2 patients have drug-induced IgA deficit, whereas HLA-A1,B8 patients have drug-independent IgA deficiency. The HLA complex on chromosome 6 seems to include the gene responsible for IgA deficiency. [33] The Additionally, a gene locus for juvenile myoclonus epilepsy and associated conditions.

Anti Epileptic Drug and Development

Epilepsy is a neurological illness that shortens life and affects 1% of people worldwide¹. Although the clinical identifier is recurrent epileptic seizures the illness process (epileptogenesis) of epilepsy starts before the occurrence of the first seizure and May potentially contribute to the development of epilepsy after seizures start. [34] Epilepsy is a diversified, with more than 15 distinct seizure types and more thirty epilepsy syndromes two and is linked to significant co morbidities, such as anxiety, depression, and higher mortality. [35] Over 15 third-generation anti-epileptic medicines (AEDs) have been introduced in the previous three decades, giving doctors and patients greater choices. for the treatment of various seizure types . However ,despite the fact that 70-80% of individuals with new-onset epilepsy eventually achieve remission , AEDs and these drugs fall short of controlling seizures in 20% to 30% of patients .[36] Additionally, no AED has been shown to stop the onset of epilepsy in individuals before their initial seizure; these medications appear to act only once to symptomatically reduce seizures they happen .In order to determine the effectiveness of a novel AED against seizures, preclinical research in animal seizure models was virtually always used until recently. Before beginning human clinical trials This strategy has proven effective and has significantly to the creation of countless highly efficient AEDs

[37]. There is no predictive value for other central nervous systems. bipolar diseases or migraine and other nervous system (CNS) problem.[38]

Reasons to monitor therapeutic medication use of AEDs

TDM has been used for these medications for more than 50 years because of the considerable interpatient pharmacokinetic heterogeneity and the saturation kinetics for the older, first-generation AEDs (carbamazepine, phenytoin, phenobarbital, primidone, and valproic acid). [39]

. Additionally, TDM is being employed to enhance therapy with a variety of novel second-generation AEDs, such as lamotrigine, levetiracetam, oxcarbazepine, topiramate, zonisamide, pregabalin, gabapentin, and others. New evidence also demonstrates the TDM's relevance for third-generation AEDs such as eslicarbazepine, lacosamide, perampanel, and brivaracetam includes the orphan medications rufinamide and stiripentol. [40] In all AEDs: Monitoring recommendations are to be taken care off.

Treatment for co morbidities other than epilepsy using AEDs is also becoming more common. These include, for instance, gabapentin and pregabalin to treat neuropathic pain and lamotrigine, valproate, and carbamazepine to treat a variety of mental problems [41]. However, these AEDs display that they are seldom monitored, despite sharing the same pharmacokinetic properties. Poor or variable adherence is a major clinical challenge and is the principal factor that contributes to variability in serum concentrations between patients. [42]

Conclusion

In order to create new and improved AEDs, innovative approaches to their discovery and development that also provide a strong argument for industry investment must be sought. Improved choices for treating epilepsy sufferers .We suggest that recent developments in our comprehension of the cellular and molecular processes causing epilepsy at this time allow for a focus on new, target-driven strategies for the development of AEDs that are more effective and well-tolerated and medicines that prevent epilepsy. This might involve using substances with unique mechanisms that were previously used in other treatment regions. Plans for future development should incorporate translation utilising comparative, preclinical proof-of-concept studies, validation using early, definitive proof-of-concept studies using "light" clinical trials and comparative Phase II studies using reliable and objective biomarkers experiments that will enable early risk reduction.

Due to underreporting of cases, variation in presentation, and a lack of rigorous diagnostic criteria, it is unknown how common AHS is; most likely, it goes undetected frequently. Both a global definition of AHS and more precise epidemiologic information are required .The pathogenetic processes of AHS are not fully understood, however this disease is most likely caused by a complicated immunological response that is mediated by the toxic metabolites of aromatic AEDs that cause cell death. These data are limited, however it is likely that patients

with unusual HLA haplotypes have a high relative chance of getting AHS. A validated, gold standard test for the diagnosis or prediction of AHS is not available, hence the diagnosis is dependent on clinical identification based on clinical history and a thorough physical examination.

REFERENCES

1. Bialer, M., White, H. Key factors in the discovery and development of new antiepileptic drugs. *Nat Rev Drug Discov* 9, 68–82 (2010). <https://doi.org/10.1038/nrd2997>.
2. Pacifici R, Zuccaro P, Iannetti P, Raucci U, Imperato C. (1995) Immunologic aspects of vigabatrin treatment in epileptic children. *Epilepsia* 36:423–426.
3. Rogawski MA, Lo'scher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. *Cold Spring Harb Perspect Med* 2016;6 pii: a022780.
4. Nardou R, Yamamoto S, Bhar A, Burnashev N, Ben-Ari Y, Khalilov I. Phenobarbital but not diazepam reduces AMPA/ kainate receptor mediated currents and exerts opposite actions on initial seizures in the neonatal rat hippocampus. *Front Cell Neurosci* 2011;5:16.
5. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. *Epilepsia* 2008;49:888–97.
6. Aarli JA. (2000) Epilepsy and the immune system. *Arch Neurol* 57:1689–1692.
7. Bartoszek M, Brenner AM, Szeffler SJ. (1987) Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. *Clin Pharmacol Ther* 42:424–432.
8. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S. (2000) Sodium valproate inhibits production of TNF- α and IL-6 and activation of NF- κ B. *Brain Res* 857:246–251.
9. Shiah IS, Yatham LN, Yeh CB, Ravindran AV. (2005) Effect of valproate on plasma levels of interleukin-6 in healthy male humans. *Int Clin Psychopharmacol* 20:295–298.
10. Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Chiarelli F. (2001) Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. *Clin Exp Med* 1:133–136.
11. Aarli JA. (2000) Epilepsy and the immune system. *Arch Neurol* 57:1689–1692.
12. Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Chiarelli F. (2001) Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. *Clin Exp Med* 1:133–136.
13. Pacifici R, Paris L, Di Carlo S, Pichini S, Zuccaro P. (1991) Immunologic aspects of carbamazepine treatment in epileptic patients. *Epilepsia* 32:122–127.
14. Gilhus NE, Lea T. (1988) Carbamazepine: effect on IgG subclasses in epileptic patients. *Epilepsia* 29:317–320.
15. Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR (January 1995). "Erythromycin-induced carbamazepine toxicity: a continuing problem". *Archives of Pediatrics & Adolescent Medicine*. 149 (1): 99–101

16. Rimmer EM, Richens A (1984). "Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy". *Lancet*. 1 (8370): 189–90. doi:10.1016/S0140-6736(84)92112-3. PMID 6141335. S2CID 54336689
17. . DEF Mexico: Sabril Archived September 14, 2005, at the Wayback Machine Diccionario de Especialdades Farmaceuticas. Edicion 49, 2003
18. Pacifici R, Zuccaro P, Iannetti P, Raucci U, Imperato C. (1995) Immunologic aspects of vigabatrin treatment in epileptic children. *Epilepsia* 36:423–426.
19. Calcaterra NE, Barrow JC (April 2014). "Classics in chemical neuroscience: diazepam (valium)". *ACS Chemical Neuroscience*. 5 (460). doi:10.1021/cn5000056. PMC 3990949. PMID 24552479
20. . Wei M, Li L, Meng R, Fan Y, Liu Y, Tao L, Liu X, Wu C. (2010) Suppressive effect of diazepam on IFN- γ production by human T cells. *Int Immunopharmacol* 10:267–271
21. Wolkenstein P, Revuz J. (1995) Drug-induced severe skin reactions: incidence, management and prevention. *Drug Saf* 13:56–68.
22. Sasaki T, Maita E. (1998) Increased bFGF level in the serum of patients with phenytoin-induced gingival overgrowth. *J Clin Periodontol* 25:42–47.
23. Mod  r T, Domeij H, Andur  n I, Mustafa M, Brunius G. (2000) Effect of phenytoin on the production of interleukin-6 and interleukin-8 in human gingival fibroblasts. *J Oral Pathol Med* 29:491–499.
24. Sume SS, Kantarci A, Lee A, Hasturk H, Trackman PC. (2010) Epithelial to mesenchymal transition in gingival overgrowth. *Am J Pathol* 177:208–218.
25. Thilo B, Stinglele R, Knudsen K, Boor R, Bien CG, Deuschl G, Lang N. (2009) A case of Rasmussen encephalitis treated with rituximab. *Nat Rev Neurol* 5:458–462.
26. Ariizumi M, Baba K, Hibio S, et al. Immunoglobulin therapy in the West syndrome. *Brain Dev (Tokyo)* 1987; 9: 422-5.
27. Hibio S. Antiepileptic effect of non-treated immunoglobulin in idiopathic Lennox Gastaut syndrome. *Nihon Univ J Med (Tokyo)* 1986; 28: 337-46.
28. Seager J, Wilson J, Jamison DL, Hayward AR, Soothill JF. IgA deficiency, epilepsy and phenytoin treatment. *Lancet* 1975; ii: 632 5.
29. Johannessen Landmark C, Patsalos PN. (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Rev Neurother* 10:119–140.
30. Patsalos PN, Froscher W, Pisani F, van Rijn CM. (2002) The importance of drug interactions in epilepsy therapy. *Epilepsia* 43:365–385.
31. Nitsch C, Klatzo I. Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. *J Neurol Sci* 1983, 59:305 22
32. Kajiwara K, Ito H, Fukumoto T. Lymphocyte infiltration into normal rat brain following hyperosmotic blood-brain opening. *J Neuroimmunol* 1990: 27:133 40.
33. . Mackworth-Young CG. Hughes GRV. Epilepsy: an early symptom of systemic lupus erythematosus. *J Neurol Neurosur~, Psychiatry* 1985: 48: 185

34. Schmidt, D. & Sillanpää, M. Evidence-based review on the natural history of the epilepsies. *Curr. Opin. Neurol.* 25, 159–163 (2012).
35. . Berg, A. T. et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia* 51, 676–685 (2010).
36. Tellez-Zenteno, J. F., Patten, S. B., Jette, N., Williams, J. & Wiebe, S. Psychiatric comorbidity in epilepsy: a population-based analysis. *Epilepsia* 48, 2336–2344 (2007).
37. Temkin, N. R. Preventing and treating posttraumatic seizures: the human experience. *Epilepsia* 50 (Suppl. 2), 10–13 (2009).
38. Schmidt, D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. *Epilept. Disord.* 14, 105–113 (2012)
39. . Johannessen Landmark C, Johannessen SI, Tomson T. Dosing strategies of antiepileptic drugs – from one dose to individualisation of treatment by implementation of therapeutic drug monitoring. *Epileptic Disord.* 2016;18(4):367–383.
40. Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions. *Epilepsy Res.* 2009;87:31–39
41. Baftiu A, Johannessen Landmark C, Rudberg Rusten I, et al. Safety aspects of utilization of antiepileptic drugs in epilepsy vs. non-epilepsy disorders. *Eur J Clin Pharmacol.* 2016;72 (10):1245–1254.
42. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. *Pharmacopsychiatry.* 2018;51:9–62.